Medtronic (MDT) stock hit with 2 downgrades after disappointing results, guidance
- Wall Street ends mixed; Salesforce selloff pressures Dow
- S&P 500 to re-test lows in H1 and then rally to 4200 on Fed pivot signal - JPMorgan
- Salesforce (CRM) drops after soft results, MS sees attractive valuation
- Snowflake (SNOW) falls as macro headwinds drag on guidance, analysts remain upbeat
- Piper Sandler says Apple (AAPL) likely lost 9M iPhone 14 units, cuts revenue estimates
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
At least two sell-side analysts cut their rating on Medtronic (NYSE: MDT) stock on Wednesday after the company’s shares closed over 5% lower yesterday following disappointing earnings.
Medtronic cut its full-year profit guidance to reflect macro pressure and FX headwinds. The company also reported a drop in revenues of 3.3% year-over-year.
“Slower than predicted procedure and supply recovery drove revenue below our expectations this quarter,” Geoff Martha, Medtronic chairman and CEO, said in the press release.
Karen Parkhill, Medtronic's chief financial officer, added:
“We continue to expect organic revenue growth acceleration, with the second half growing faster than the first. However, given a slower pace of market and supply recovery, we’re reducing our revenue expectations for the remainder of the year.”
Following yesterday’s news, Citi and Oppenheimer downgraded Medtronic stock to send shares nearly 1% lower today.
Citi analyst Joanne Wuensch downgraded to Neutral from Buy with a price target of $85 per share, down from $108.
“It is getting harder for us to support the stock,” said Wuensch in a downgrade note.
“This was one of those quarters when investors (and we) question the ability of Medtronic to deliver MSD revenue growth over time. While we believe that management has a handle on the headwinds negatively impacting FY2Q23 resulting in the FY23 guide down, the timing to resolution is less certain,” the analyst added.
Similarly, Oppenheimer analyst Steven Lichtman moved to Perform from Outperform with an $85 price target.
“We continue to see solid long-term pipeline opportunities and valuation is supportive, but with visibility on near-term fundamentals still low, we step to the sideline,” Lichtman wrote.
With Medtronic shares trading below $80 apiece, the bears are now eyeing a move toward multi-year lows at $72.13.
By Senad Karaahmetovic
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dollar General (DG) shares slide as profit impacted by increased product costs
- Elastic (ESTC) shares drop after guidance cut; Canaccord sees buying opportunity
- Wolfe Research says questions around demand drove CrowdStrike (CRWD) weakness
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades, Hot Downgrades, Hot List
Related EntitiesCiti, Earnings, Senad Karaahmetovic
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!